{"id":"mycophenolic-acid-dose-reduction","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (diarrhea, nausea, vomiting)"},{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL866","moleculeType":"Small molecule","molecularWeight":"320.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mycophenolic acid is a selective inhibitor of IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By reducing the dose, this approach aims to maintain immunosuppressive efficacy while decreasing exposure-related adverse effects. Dose reduction strategies are typically employed in transplant recipients to optimize the balance between rejection prevention and tolerability.","oneSentence":"Mycophenolic acid dose reduction involves lowering the administered dose of mycophenolic acid, an immunosuppressant that inhibits inosine monophosphate dehydrogenase (IMPDH) to reduce T and B lymphocyte proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:43.677Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients (kidney, heart, liver)"},{"name":"Autoimmune diseases requiring immunosuppression"}]},"trialDetails":[{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT01659606","phase":"PHASE2","title":"Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2012-07","conditions":"Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome","enrollment":40},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT05622318","phase":"PHASE2","title":"De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-08-29","conditions":"Graft-versus-host Disease","enrollment":56},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT06001385","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2023-12-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia","enrollment":313},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT02782546","phase":"PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-30","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT05115630","phase":"PHASE2","title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-08","conditions":"Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT05088356","phase":"PHASE1","title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-09-07","conditions":"Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia","enrollment":60},{"nctId":"NCT03128034","phase":"PHASE1, PHASE2","title":"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2017-10-24","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT06615050","phase":"PHASE3","title":"A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-04-02","conditions":"Graft-versus-host Disease (GVHD)","enrollment":572},{"nctId":"NCT01349101","phase":"PHASE2","title":"A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-02-10","conditions":"Hematological Malignancies","enrollment":78},{"nctId":"NCT07091175","phase":"PHASE2","title":"Dupilumab Therapy in Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-11-27","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent","enrollment":66},{"nctId":"NCT06926595","phase":"PHASE2","title":"Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-02-01","conditions":"Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation","enrollment":41},{"nctId":"NCT03216967","phase":"PHASE4","title":"Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2018-01-15","conditions":"BK Virus Nephropathy After Kidney Transplantation","enrollment":130},{"nctId":"NCT07053891","phase":"","title":"LUPKYNIS Drug-use Results Survey","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2025-09-17","conditions":"Lupus Nephritis","enrollment":400},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT07074951","phase":"NA","title":"Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2013-03-10","conditions":"Primary IgA-nephropathy, High-risk, Caucasians","enrollment":240},{"nctId":"NCT04473911","phase":"PHASE1","title":"Haplo Peripheral Blood Sct In GVHD Prevention","status":"COMPLETED","sponsor":"Zachariah Michael DeFilipp","startDate":"2020-08-14","conditions":"GVHD, AML, ALL","enrollment":25},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT05805605","phase":"PHASE2","title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-01","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia","enrollment":56},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT06280950","phase":"PHASE2","title":"Expanding Liver Transplant Immunosuppression Minimization Via Everolimus","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-12","conditions":"Liver Transplant","enrollment":340},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT06310837","phase":"NA","title":"Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-03-27","conditions":"Uveitis","enrollment":128},{"nctId":"NCT02548468","phase":"PHASE1","title":"Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2015-11-20","conditions":"Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Stage IIB Mycosis Fungoides and Sezary Syndrome","enrollment":""},{"nctId":"NCT05365672","phase":"PHASE2","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","status":"RECRUITING","sponsor":"TolerogenixX GmbH","startDate":"2022-05-04","conditions":"Kidney Transplantation","enrollment":126},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT05060991","phase":"PHASE4","title":"Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-09-24","conditions":"COVID-19, Immunosuppression, Vaccine Response Impaired","enrollment":50},{"nctId":"NCT05298358","phase":"PHASE1","title":"RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-11-18","conditions":"Systemic Sclerosis","enrollment":1},{"nctId":"NCT04106830","phase":"","title":"Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2019-01-01","conditions":"NMO Spectrum Disorder, MRI, Multiple Sclerosis","enrollment":1000},{"nctId":"NCT06297096","phase":"PHASE3","title":"Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland","startDate":"2025-01-01","conditions":"Systemic Sclerosis, Interstitial Lung Disease","enrollment":86},{"nctId":"NCT06650124","phase":"PHASE2, PHASE3","title":"Induction of Remission in Autoimmune Hepatitis With Azathioprine vs. MMF","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-11-01","conditions":"Autoimmune Hepatitis","enrollment":108},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT02550652","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-13","conditions":"Lupus Nephritis","enrollment":126},{"nctId":"NCT01050855","phase":"PHASE2","title":"Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2008-01","conditions":"Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies","enrollment":75},{"nctId":"NCT03902665","phase":"PHASE2","title":"Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-03-15","conditions":"Acute Myeloid Leukemia, Adult","enrollment":19},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT03959241","phase":"PHASE3","title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-06-25","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia","enrollment":431},{"nctId":"NCT03128359","phase":"PHASE2","title":"High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2017-05-30","conditions":"Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":38},{"nctId":"NCT04177095","phase":"PHASE4","title":"Immune Monitoring to Facilitate Belatacept Monotherapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-02-11","conditions":"Kidney Transplant Rejection, Immunosuppression","enrollment":17},{"nctId":"NCT02248597","phase":"PHASE2","title":"Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-02-25","conditions":"Graft Versus Host Disease, Hematopoietic/Lymphoid Cancer","enrollment":27},{"nctId":"NCT04888741","phase":"PHASE2","title":"Methods of T Cell Depletion Trial (MoTD)","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":400},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT01044745","phase":"PHASE2","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-12-10","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT00816413","phase":"PHASE1, PHASE2","title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-09","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT00057954","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-11-09","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT05073822","phase":"PHASE1, PHASE2","title":"NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation","status":"WITHDRAWN","sponsor":"University College, London","startDate":"2023-02-20","conditions":"Renal Transplant Rejection, Renal Transplant Infection","enrollment":""},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT04585152","phase":"PHASE2","title":"Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.","status":"UNKNOWN","sponsor":"Istituto Giannina Gaslini","startDate":"2020-10-15","conditions":"Nephrotic Syndrome Steroid-Dependent","enrollment":160},{"nctId":"NCT04810156","phase":"PHASE2","title":"Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis","status":"UNKNOWN","sponsor":"Inge Marie Svane","startDate":"2021-04-07","conditions":"Hepatitis, Drug-Induced","enrollment":60},{"nctId":"NCT00739141","phase":"PHASE2","title":"Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-08-12","conditions":"Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma","enrollment":86},{"nctId":"NCT02736227","phase":"NA","title":"Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-03","conditions":"Liver Transplantation","enrollment":28},{"nctId":"NCT03434704","phase":"PHASE2","title":"Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole","status":"COMPLETED","sponsor":"Ciceri Fabio","startDate":"2018-06-18","conditions":"Transplant-Related Hematologic Malignancy, Leukemia, Acute, Myelodysplastic Syndromes","enrollment":10},{"nctId":"NCT02088931","phase":"PHASE1","title":"Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-03","conditions":"Late Complication From Kidney Transplant","enrollment":3},{"nctId":"NCT05415579","phase":"","title":"Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)","status":"NOT_YET_RECRUITING","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2022-06-20","conditions":"Demyelinating Diseases of the Central Nervous System (DDC)","enrollment":2000},{"nctId":"NCT01935128","phase":"PHASE4","title":"Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2013-07-03","conditions":"Renal Transplant","enrollment":55},{"nctId":"NCT05338177","phase":"PHASE1","title":"Pilot Trial on Immunosuppression Modulation to Increase SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2021-11-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT03303989","phase":"PHASE2","title":"REduCing Immunogenicity to PegloticasE (RECIPE) Study","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-06-14","conditions":"Gout Chronic","enrollment":35},{"nctId":"NCT05207358","phase":"PHASE4","title":"Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis","status":"RECRUITING","sponsor":"Institutul Clinic Fundeni","startDate":"2022-03-02","conditions":"Lupus Nephritis","enrollment":30},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT01597778","phase":"PHASE3","title":"Double Cord Versus Haploidentical (BMT CTN 1101)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2012-06","conditions":"Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma","enrollment":368},{"nctId":"NCT05129410","phase":"PHASE4","title":"Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2020-12-01","conditions":"Idiopathic Inflammatory Myopathy, Interstitial Lung Disease","enrollment":20},{"nctId":"NCT04961229","phase":"PHASE4","title":"Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response","status":"UNKNOWN","sponsor":"dafna yahav","startDate":"2021-10","conditions":"COVID-19 Acute Respiratory Distress Syndrome, Immunosuppression","enrollment":504},{"nctId":"NCT03018223","phase":"PHASE1","title":"Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-01-31","conditions":"Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia","enrollment":32},{"nctId":"NCT04622956","phase":"PHASE1, PHASE2","title":"GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-07","conditions":"Graft Vs Host Disease, Hematopoietic Neoplasm","enrollment":47},{"nctId":"NCT04670926","phase":"NA","title":"Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test","status":"UNKNOWN","sponsor":"Transplant Genomics, Inc.","startDate":"2021-06-03","conditions":"Kidney Transplant Rejection, Immunosuppression","enrollment":75},{"nctId":"NCT02435901","phase":"PHASE1, PHASE2","title":"HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2008-12","conditions":"Sickle Cell Disease, Beta Thalassemia-Major","enrollment":29},{"nctId":"NCT00919503","phase":"PHASE2","title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-07-31","conditions":"Non-Neoplastic Hematologic and Lymphocytic Disorder","enrollment":98},{"nctId":"NCT01020539","phase":"PHASE1","title":"Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09-11","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia","enrollment":18},{"nctId":"NCT01729494","phase":"PHASE4","title":"Belatacept Early Steroid Withdrawal Trial","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-09","conditions":"Renal Transplantation","enrollment":316},{"nctId":"NCT03492255","phase":"NA","title":"CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid","status":"TERMINATED","sponsor":"University of Sao Paulo General Hospital","startDate":"2018-04-12","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":49},{"nctId":"NCT01434472","phase":"PHASE2","title":"High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-11-16","conditions":"Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT01685411","phase":"NA","title":"Busulfan and Cyclophosphamide Followed By ALLO BMT","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT01244659","phase":"PHASE3","title":"A Randomized Study Assess the Safety and Efficacy of Tacrolimus vs Prograf® in Renal Transplantation Treatment","status":"WITHDRAWN","sponsor":"EMS","startDate":"2014-05","conditions":"Renal Transplant","enrollment":""},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT01921218","phase":"PHASE3","title":"Belatacept Therapy for the Failing Renal Allograft","status":"COMPLETED","sponsor":"Andrew B Adams","startDate":"2013-08","conditions":"Failing Renal Allograft","enrollment":13},{"nctId":"NCT01064791","phase":"PHASE2","title":"Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Renal Transplantation","enrollment":298},{"nctId":"NCT01062555","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor Sparing After Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-10-01","conditions":"CNI Side Effects","enrollment":527},{"nctId":"NCT02181478","phase":"EARLY_PHASE1","title":"Intra-Osseous Co-Transplant of UCB and hMSC","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-07-22","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":6},{"nctId":"NCT03262441","phase":"PHASE2","title":"MMF for HIV Reservoir Reduction","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-02-12","conditions":"Human Immunodeficiency Virus I Infection","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":178,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CellCept","Myfortic"],"phase":"marketed","status":"active","brandName":"Mycophenolic acid dose reduction","genericName":"Mycophenolic acid dose reduction","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycophenolic acid dose reduction involves lowering the administered dose of mycophenolic acid, an immunosuppressant that inhibits inosine monophosphate dehydrogenase (IMPDH) to reduce T and B lymphocyte proliferation. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver), Autoimmune diseases requiring immunosuppression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}